<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34264761</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1947-5543</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Biopreservation and biobanking</Title><ISOAbbreviation>Biopreserv Biobank</ISOAbbreviation></Journal><ArticleTitle>Analysis of Biospecimen Demand and Utilization of Samples from the National Amyotrophic Lateral Sclerosis Biorepository.</ArticleTitle><Pagination><StartPage>432</StartPage><EndPage>437</EndPage><MedlinePgn>432-437</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/bio.2021.0039</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rare neurological condition affecting upper and lower motor neurons. The National ALS Biorepository (referred to as the Biorepository) was initiated in 2015, with biospecimen collection beginning in 2017, as a repository for biospecimens for future ALS research. To help ensure the usefulness of the Biorepository, a biospecimen demand analysis is conducted on an annual basis, as well as an analysis of the utilization of the Biorepository. To determine the types of biospecimens to be collected for the Biorepository, an in-depth initial examination occurred followed by ongoing biospecimen demand and utilization analyses. The initial examination included input from an expert panel, discussions with ALS research experts, review of other ALS biorepositories, assessment of biospecimen demand, and analysis of the biospecimen types historically used in ALS research. Of all biospecimen types reported in the literature, the most frequently used were DNA, postmortem spinal cord, blood, and cerebrospinal fluid; while the frequently reported types of biospecimens used in ALS-related grants were induced pluripotent stem cells, brain, blood, and spinal cord. Continuous analysis of potential sample demand and tissues collected, based on an analysis of the literature and funded grants, and actual sample requests can assist the Biorepository in ensuring that the appropriate samples are available for researchers when they are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bledsoe</LastName><ForeName>Marianna J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Independent Consultant, Colorado Springs, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rechtman</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8629-3881</Identifier><AffiliationInfo><Affiliation>McKing Consulting Corporation, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>McKing Consulting Corporation, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>D Kevin</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Wendy E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>McKing Consulting Corporation, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biopreserv Biobank</MedlineTA><NlmUniqueID>101507284</NlmUniqueID><ISSNLinking>1947-5543</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biorepository</Keyword><Keyword MajorTopicYN="N">biospecimen</Keyword><Keyword MajorTopicYN="N">utilization</Keyword></KeywordList><CoiStatement>Author Disclosure Statement. No conflicting financial interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>15</Day><Hour>17</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34264761</ArticleId><ArticleId IdType="mid">NIHMS1800834</ArticleId><ArticleId IdType="pmc">PMC9082877</ArticleId><ArticleId IdType="doi">10.1089/bio.2021.0039</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2011;82:623&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">21047878</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, et al. Prevalence of amyotrophic lateral sclerosis&#x2014;United States, 2014. MMWR Morb Mortal Wkly Rep 2018;67:216&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858037</ArticleId><ArticleId IdType="pubmed">29470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechtman L, Jordan H, Wagner L, et al. Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4389704</ArticleId><ArticleId IdType="pubmed">25482100</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari R, Kuhad A, Kuhad A. Edaravone: A new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc) 2018;54:349&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">29998226</ArticleId></ArticleIdList></Reference><Reference><Citation>Antao VC, Horton DK. The National Amyotrophic Lateral Sclerosis (ALS) Registry. J Environ Health 2012;75:28&#x2013;30.</Citation></Reference><Reference><Citation>Horton DK, Kaye W, Wagner L. Integrating a biorepository into the National Amyotrophic Lateral Sclerosis Registry. J Environ Health 2016;79:38&#x2013;40.</Citation></Reference><Reference><Citation>Cadigan RJ, Juengst E, Davis A, et al. Underutilization of specimens in biobanks: An ethical as well as a practical concern?. Genet Med 2014;16:738&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189984</ArticleId><ArticleId IdType="pubmed">24763288</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson GE, Cadigan RJ, Edwards TP, et al. Characterizing biobank organizations in the U.S.: Results from a national survey. Genome Med 2013;5:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706795</ArticleId><ArticleId IdType="pubmed">23351549</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson MK, Goldring K, Simeon-Dubach D. Advancing professionalization of biobank business operations: Performance and utilization. Biopreserv Biobank 2019;17:213&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588106</ArticleId><ArticleId IdType="pubmed">31188630</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadigan RJ, Lassiter D, Haldeman K, Conlon I, Reavely E, Henderson GE. Neglected ethical issues in biobank management: Results from a U.S. study. Life Sci Soc Policy 2013;9:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4228790</ArticleId><ArticleId IdType="pubmed">25401081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bledsoe MJ, Sexton KC. Ensuring effective utilization of biospecimens: Design, marketing, and other important approaches. Biopreserv Biobank 2019;17:248&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588104</ArticleId><ArticleId IdType="pubmed">31188625</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health. Research portfolio online reporting tools. Available at: https://report.nih.gov (last accessed March 4, 2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>